UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On March 17, 2022, Xometry, Inc. issued a press release announcing its fourth quarter and full year ended December 31, 2021 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 2.02 and in the accompanying Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. |
Description |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
XOMETRY, INC. |
|
|
|
|
Date: |
March 17, 2022 |
By: |
/s/ Randolph Altschuler |
|
|
|
Randolph Altschuler |
Exhibit 99.1
Xometry Reports Fourth Quarter and Full Year 2021 Results
ROCKVILLE, MD., March 17, 2022 /Globe Newswire/ -- Xometry, Inc. (NASDAQ:XMTR), a leading global AI enabled digital manufacturing marketplace, today reported financial results for the fourth quarter ended December 31, 2021.
“In Q4 2021, Xometry continued to demonstrate strong growth across the board with accelerated demand from our larger customers. Our AI-driven platform gets smarter with each new data point leading to record gross margin,” said Randy Altschuler, Xometry’s CEO. “Although we are still in the early innings of the secular digitization of the manufacturing industry, Xometry has become the digital marketplace connecting buyers with sellers to unleash limitless product innovation.”
Fourth Quarter Financial Highlights
1
Fourth Quarter Business Highlights
Full Year Financial Highlights
Full Year Business Highlights
2
Financial Summary
(In thousands, except per share amounts)
|
|
For the Three Months Ended December 31, |
|
|
|
|
|
For the Year Ended December 31, |
|
|
|
|
||||||||||||
|
|
2021 |
|
|
2020 |
|
|
% Change |
|
|
2021 |
|
|
2020 |
|
|
% Change |
|
||||||
|
|
(unaudited) |
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|||||||||
Revenue |
|
$ |
67,098 |
|
|
$ |
37,980 |
|
|
|
77 |
% |
|
$ |
218,336 |
|
|
$ |
141,406 |
|
|
|
54 |
% |
Gross profit |
|
|
20,937 |
|
|
|
9,479 |
|
|
|
121 |
% |
|
|
57,141 |
|
|
|
33,286 |
|
|
|
72 |
% |
Net loss |
|
|
(23,907 |
) |
|
|
(10,178 |
) |
|
|
135 |
% |
|
|
(61,381 |
) |
|
|
(31,085 |
) |
|
|
97 |
% |
EPS—basic and diluted |
|
|
(0.53 |
) |
|
|
(1.34 |
) |
|
|
(60 |
)% |
|
|
(2.33 |
) |
|
|
(5.32 |
) |
|
|
(56 |
)% |
Adjusted EBITDA (Non-GAAP)(1) |
|
|
(11,854 |
) |
|
|
(6,590 |
) |
|
|
80 |
% |
|
|
(39,757 |
) |
|
|
(23,498 |
) |
|
|
69 |
% |
Key Operating Metrics(2):
|
|
As of December 31, |
|
|||||||||
|
|
2021 |
|
|
2020 |
|
|
% |
|
|||
|
|
|
|
|
|
|
|
|
|
|||
Active Buyers(3) |
|
|
28,130 |
|
|
|
18,846 |
|
|
|
49 |
% |
Percentage of Revenue from Existing Accounts(3) |
|
|
95 |
% |
|
|
95 |
% |
|
|
— |
% |
Accounts with Last Twelve-Months Spend of at Least $50,000(3) |
|
|
701 |
|
|
|
389 |
|
|
|
80 |
% |
|
|
|
|
|
|
|
|
|
|
|||
Subsequent to Fourth Quarter 2021
On February 4, 2022, the Company completed a private offering of $250 million aggregate principal amount of 1.00% Convertible Senior Notes due 2027 (the “Initial Notes”). The Initial Notes were issued pursuant to an indenture, dated February 4, 2022 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.
On February 10, 2022, the Company issued an additional $37.5 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2027 (the “Additional Notes”) to the initial purchasers named in the purchase agreement. The issuance of the Additional Notes was pursuant to the initial purchasers’ exercise in full of their 13-day option to purchase Additional Notes granted in the original offering of $250 million aggregate principal amount of 1.00% Convertible Senior Notes due 2027. The proceeds from the Initial Notes and the Additional Notes (collectively referred to as the “Notes”) are expected to be used for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds for acquisitions of, or strategic investments in, complementary businesses, products, services, or technologies. However, the Company does not have agreements or commitments with respect to any such acquisition or strategic investment at this time. The Notes are general unsecured obligations of the Company and will mature on February 1, 2027, unless earlier converted, redeemed or repurchased. Interest on the Notes will accrue at a rate of 1.00% per year from February 4, 2022 and will be payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2022. In connection with the Notes offering, the Company received net cash proceeds of approximately $278.9 million, after deducting the initial purchasers discounts and commissions.
3
Financial Guidance and Outlook:
|
|
Q1 2022 |
|
|
FY 2022 |
|
||||||||||
|
|
(in millions) |
|
|||||||||||||
|
|
Low |
|
|
High |
|
|
Low |
|
|
High |
|
||||
Revenue |
|
$ |
81.0 |
|
|
$ |
82.0 |
|
|
$ |
390.0 |
|
|
$ |
400.0 |
|
Adjusted EBITDA |
|
$ |
(13.5 |
) |
|
$ |
(12.5 |
) |
|
$ |
(36.0 |
) |
|
$ |
(32.0 |
) |
Use of Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”), Xometry, Inc. ("Xometry", the "Company", "we" or "our") uses Adjusted EBITDA, a non-GAAP financial measure, as described below. This non-GAAP financial measure is presented to enhance the user’s overall understanding of Xometry’s financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The non-GAAP financial measure presented in this release, together with the GAAP financial results, are the primary measures used by the Company’s management and board of directors to understand and evaluate the Company’s financial performance and operating trends, including period-to-period comparisons, because they exclude certain expenses and gains that management believes are not indicative of the Company’s core operating results. Management also uses this measure to prepare and update the Company’s short and long term financial and operational plans, to evaluate investment decisions, and in its discussions with investors, commercial bankers, equity research analysts and other users of the Company’s financial statements. Accordingly, the Company believes that this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating the Company’s operating results in the same manner as the Company’s management and in comparing operating results across periods and to those of Xometry’s peer companies. In addition, from time to time we may present adjusted information (for example, revenue growth) to exclude the impact of certain gains, losses or other changes that affect period-to-period comparability of our operating performance.
The use of non-GAAP financial measures has certain limitations because they do not reflect all items of income and expense, or cash flows, that affect the Company’s financial performance and operations. An additional limitation of non-GAAP financial measures is that they do not have standardized meanings, and therefore other companies, including peer companies, may use the same or similarly named measures but exclude or include different items or use different computations. Management compensates for these limitations by reconciling these non-GAAP financial measures to their most comparable GAAP financial measures in the tables captioned “Reconciliations of Non-GAAP Financial Measures” included at the end of this release. Investors and others are encouraged to review the Company’s financial information in its entirety and not rely on a single financial measure.
4
Key Terms for our Key Metrics and Non-GAAP Financial Measures
The Company defines Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net income (loss) excluding interest income (expense), income tax (expense) benefit, and certain other non-cash or non-recurring items impacting net loss from time to time, principally comprised of depreciation and amortization, stock-based compensation, transaction costs, charitable contributions, income from unconsolidated joint venture and impairment charges. Management believes that the exclusion of certain expenses and gains in calculating Adjusted EBITDA provides a useful measure for period-to-period comparisons of the Company’s underlying core revenue and operating costs that is focused more closely on the current costs necessary to operate the Company’s businesses, and reflects its ongoing business in a manner that allows for meaningful analysis of trends. Management also believes that excluding certain non-cash charges can be useful because the amounts of such expenses is the result of long-term investment decisions made in previous periods rather than day-to-day operating decisions.
Active Buyers: The Company defines “buyers” as individuals who have placed an order to purchase on-demand parts or assemblies on our platform. The Company defines Active Buyers as the number of buyers who have made at least one purchase on our marketplace during the last twelve months.
Percentage of Revenue from Existing Accounts: The Company defines “accounts” as an individual entity, such as a sole proprietor with a single buyer or corporate entities with multiple buyers, having purchased at least one part on our marketplace. The Company defines an existing account as an account where at least one buyer has made a purchase on our marketplace.
Accounts with Last Twelve-Month Spend of At Least $50,000: The Company defines Accounts with Last Twelve-Month Spend of At Least $50,000 as an account that has spent at least $50,000 on our marketplace in the most recent twelve-month period.
About Xometry
Xometry (XMTR) powers the industries of today and tomorrow by connecting the people with big ideas to the manufacturers who can bring them to life. Xometry’s digital marketplace gives manufacturers the critical resources they need to grow their business while also making it easy for buyers at Fortune 1000 companies to tap into global manufacturing capacity. Learn more at www.xometry.com or follow @xometry.
Conference Call
The Company will discuss its fourth quarter and full year 2021 financial results during a teleconference on 3/17/2022, at 5:00 PM ET/2:00 PM PT. The conference call can be accessed in the U.S. at 877-313-2061 or outside the U.S. at 470-495-9537 with the conference ID# 7397803. A live audio webcast of the call will also be available simultaneously at investors.xometry.com. Following completion of the call, a recorded replay of the teleconference will be available in the investor relations section of Xometry's website. The earnings webcast presentation will be archived within the Investor Relations section of Xometry's website.
5
Cautionary Information Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “would,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, our beliefs regarding our financial position and operating performance, including our outlook and guidance for the first quarter and full year 2022, certain expected synergies from recent acquisitions and demand for our marketplace in general. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks and uncertainties related to: competition, managing our growth, financial performance, including the impact of the COVID-19 pandemic on our business and operations and our ability to forecast our performance due to our limited operating history and the COVID-19 pandemic, investments in new products or offerings, our ability to attract buyers and sellers to our marketplace, legal proceedings and regulatory matters and developments, any future changes to our business or our financial or operating model, and our brand and reputation. The forward-looking statements contained in this press release are also subject to other risks and uncertainties that could cause actual results to differ from the results predicted, including those more fully described in our filings with the SEC, including our Annual Report on Form 10-K for the period ended December 31, 2021. All forward-looking statements in this press release are based on information available to Xometry and assumptions and beliefs as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
# # #
(Tables Follow)
|
|
Investor Contact: |
Media Contact: |
Shawn Milne VP Investor Relations 240-335-8132 shawn.milne@xometry.com |
Matthew Hutchison Corporate Communications for Xometry 415-583-2119 matthew.hutchinson@xometry.com |
|
|
6
Xometry, Inc. and Subsidiaries
Consolidated Balance Sheets
(In thousands, except share and per share data)
|
|
December 31, |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
86,262 |
|
|
$ |
59,874 |
|
Marketable securities |
|
|
30,465 |
|
|
|
— |
|
Accounts receivable, less allowance for doubtful accounts of $0.8 million and $0.6 million as of December 31, 2021 and 2020, respectively |
|
|
32,427 |
|
|
|
14,574 |
|
Inventory |
|
|
2,033 |
|
|
|
2,294 |
|
Prepaid expenses |
|
|
6,664 |
|
|
|
913 |
|
Deferred sales commissions |
|
|
5,283 |
|
|
|
— |
|
Other current assets |
|
|
297 |
|
|
|
— |
|
Total current assets |
|
|
163,431 |
|
|
|
77,655 |
|
Property and equipment, net |
|
|
10,287 |
|
|
|
6,113 |
|
Operating lease right-of-use assets |
|
|
27,489 |
|
|
|
1,922 |
|
Investment in unconsolidated joint venture |
|
|
4,198 |
|
|
|
— |
|
Intangible assets, net |
|
|
41,736 |
|
|
|
1,652 |
|
Goodwill |
|
|
254,672 |
|
|
|
833 |
|
Other assets |
|
|
773 |
|
|
|
788 |
|
Total assets |
|
$ |
502,586 |
|
|
$ |
88,963 |
|
Liabilities, convertible preferred stock and stockholders’ equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
12,718 |
|
|
$ |
5,640 |
|
Accrued expenses |
|
|
30,905 |
|
|
|
13,606 |
|
Contract liabilities |
|
|
7,863 |
|
|
|
2,355 |
|
Operating lease liabilities, current portion |
|
|
5,549 |
|
|
|
1,013 |
|
Finance lease liabilities, current portion |
|
|
2 |
|
|
|
14 |
|
Short-term debt |
|
|
— |
|
|
|
15,753 |
|
Total current liabilities |
|
|
57,037 |
|
|
|
38,381 |
|
Operating lease liabilities, net of current portion |
|
|
16,920 |
|
|
|
1,118 |
|
Income taxes payable |
|
|
1,468 |
|
|
|
— |
|
Other liabilities |
|
|
1,678 |
|
|
|
— |
|
Total liabilities |
|
|
77,103 |
|
|
|
39,499 |
|
Commitments and contingencies (Note 12) |
|
|
|
|
|
|
||
Convertible preferred stock |
|
|
|
|
|
|
||
Convertible preferred stock, $0.000001 par value, Seed-1, Seed-2, Series A-1, Series A-2, Series B, Series C, Series D and Series E. Authorized; zero shares and 27,970,966 shares, zero shares and 27,758,941 shares issued and outstanding as of December 31, 2021 and 2020, respectively |
|
|
— |
|
|
|
160,713 |
|
Stockholders’ equity (deficit) |
|
|
|
|
|
|
||
Preferred stock, $0.000001 par value. Authorized; 50,000,000 shares and zero shares; zero shares issued and outstanding as of December 31, 2021 and 2020, respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.000001 par value. Authorized; zero shares and 42,000,000 shares; zero shares and 7,755,782 shares issued and outstanding as of December 31, 2021 and 2020, respectively |
|
|
— |
|
|
|
— |
|
Class A Common stock, $0.000001 par value. Authorized; 750,000,000 shares and zero shares |
|
|
— |
|
|
|
— |
|
Class B Common stock, $0.000001 par value. Authorized; 5,000,000 shares and zero shares, 2,676,154 shares and zero shares issued and outstanding as of December 31, 2021 and 2020, respectively |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
597,641 |
|
|
|
503 |
|
Accumulated other comprehensive income |
|
|
149 |
|
|
|
210 |
|
Accumulated deficit |
|
|
(173,341 |
) |
|
|
(111,962 |
) |
Total stockholders’ equity (deficit) |
|
|
424,449 |
|
|
|
(111,249 |
) |
Noncontrolling interest |
|
|
1,034 |
|
|
|
— |
|
Total equity (deficit) |
|
|
425,483 |
|
|
|
(111,249 |
) |
Total liabilities, convertible preferred stock and stockholders’ equity |
|
$ |
502,586 |
|
|
$ |
88,963 |
|
7
Xometry, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
|
|
(unaudited) |
|
|
(unaudited) |
|
|
|
|
|||||||
Revenue |
|
$ |
67,098 |
|
|
$ |
37,980 |
|
|
$ |
218,336 |
|
|
$ |
141,406 |
|
Cost of revenue |
|
|
46,161 |
|
|
|
28,501 |
|
|
|
161,195 |
|
|
|
108,120 |
|
Gross profit |
|
|
20,937 |
|
|
|
9,479 |
|
|
|
57,141 |
|
|
|
33,286 |
|
Sales and marketing |
|
|
13,173 |
|
|
|
6,725 |
|
|
|
39,422 |
|
|
|
22,567 |
|
Operations and support |
|
|
8,089 |
|
|
|
3,973 |
|
|
|
23,683 |
|
|
|
14,111 |
|
Product development |
|
|
5,648 |
|
|
|
3,307 |
|
|
|
17,780 |
|
|
|
12,186 |
|
General and administrative |
|
|
16,601 |
|
|
|
3,255 |
|
|
|
34,942 |
|
|
|
12,046 |
|
Impairment of goodwill and intangible assets |
|
|
— |
|
|
|
1,592 |
|
|
|
— |
|
|
|
1,592 |
|
Total operating expenses |
|
|
43,511 |
|
|
|
18,852 |
|
|
|
115,827 |
|
|
|
62,502 |
|
Loss from operations |
|
|
(22,574 |
) |
|
|
(9,373 |
) |
|
|
(58,686 |
) |
|
|
(29,216 |
) |
Other (expenses) income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
(53 |
) |
|
|
(365 |
) |
|
|
(852 |
) |
|
|
(1,089 |
) |
Interest and dividend income |
|
|
525 |
|
|
|
— |
|
|
|
982 |
|
|
|
— |
|
Other expenses |
|
|
(1,846 |
) |
|
|
(440 |
) |
|
|
(2,866 |
) |
|
|
(780 |
) |
Income from unconsolidated joint venture |
|
|
41 |
|
|
|
— |
|
|
|
41 |
|
|
|
— |
|
Total other expenses |
|
|
(1,333 |
) |
|
|
(805 |
) |
|
|
(2,695 |
) |
|
|
(1,869 |
) |
Net loss |
|
|
(23,907 |
) |
|
|
(10,178 |
) |
|
|
(61,381 |
) |
|
|
(31,085 |
) |
Deemed dividend to preferred stockholders |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(8,801 |
) |
Net loss attributable to noncontrolling interest |
|
|
2 |
|
|
|
— |
|
|
|
2 |
|
|
|
— |
|
Net loss attributable to common stockholders |
|
$ |
(23,905 |
) |
|
$ |
(10,178 |
) |
|
$ |
(61,379 |
) |
|
$ |
(39,886 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.53 |
) |
|
$ |
(1.34 |
) |
|
$ |
(2.33 |
) |
|
$ |
(5.32 |
) |
Weighted-average number of shares outstanding used to compute |
|
|
44,995,598 |
|
|
|
7,572,935 |
|
|
|
26,318,349 |
|
|
|
7,492,876 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign currency translation |
|
$ |
(38 |
) |
|
$ |
— |
|
|
$ |
(61 |
) |
|
$ |
210 |
|
Total other comprehensive (loss) income |
|
|
(38 |
) |
|
|
— |
|
|
|
(61 |
) |
|
|
210 |
|
Net loss |
|
|
(23,907 |
) |
|
|
(10,178 |
) |
|
|
(61,381 |
) |
|
|
(31,085 |
) |
Comprehensive loss |
|
|
(23,945 |
) |
|
|
(10,178 |
) |
|
|
(61,442 |
) |
|
|
(30,875 |
) |
Comprehensive loss attributable to noncontrolling interest |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total comprehensive loss attributable to common stockholders |
|
$ |
(23,945 |
) |
|
$ |
(10,178 |
) |
|
$ |
(61,442 |
) |
|
$ |
(30,875 |
) |
8
Xometry, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(In thousands)
|
|
Year Ended December 31, |
|
|||||||||
|
|
2021 |
|
|
2020 |
|
|
2019 |
|
|||
Cash flows from operating activities: |
|
(unaudited) |
|
|
|
|
|
|
|
|||
Net loss |
|
$ |
(61,381 |
) |
|
$ |
(31,085 |
) |
|
$ |
(30,994 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|||
Depreciation and amortization |
|
|
3,596 |
|
|
|
3,120 |
|
|
|
1,847 |
|
Impairment of goodwill and intangible assets |
|
|
— |
|
|
|
1,592 |
|
|
|
1,719 |
|
Reduction in carrying amount of right-of-use asset |
|
|
1,056 |
|
|
|
1,045 |
|
|
|
647 |
|
Stock based compensation |
|
|
7,395 |
|
|
|
1,006 |
|
|
|
544 |
|
Non-cash interest expense |
|
|
111 |
|
|
|
320 |
|
|
|
259 |
|
Loss on debt extinguishment |
|
|
272 |
|
|
|
— |
|
|
|
— |
|
Income from unconsolidated joint venture |
|
|
(41 |
) |
|
|
— |
|
|
|
— |
|
Donation of common stock |
|
|
2,226 |
|
|
|
— |
|
|
|
— |
|
Unrealized loss on marketable securities |
|
|
2,002 |
|
|
|
— |
|
|
|
— |
|
Inventory write off |
|
|
— |
|
|
|
(15 |
) |
|
|
(141 |
) |
Loss (gain) on sale of property and equipment |
|
|
20 |
|
|
|
— |
|
|
|
(128 |
) |
Accretion of discount on short-term investments |
|
|
— |
|
|
|
— |
|
|
|
(37 |
) |
Deferred taxes benefit |
|
|
(179 |
) |
|
|
— |
|
|
|
— |
|
Changes in other assets and liabilities: |
|
|
|
|
|
|
|
|
|
|||
Accounts receivable, net |
|
|
(11,117 |
) |
|
|
(2,130 |
) |
|
|
(5,505 |
) |
Inventory |
|
|
293 |
|
|
|
(956 |
) |
|
|
(555 |
) |
Prepaid expenses |
|
|
(4,025 |
) |
|
|
(210 |
) |
|
|
(2 |
) |
Deferred commissions |
|
|
147 |
|
|
|
— |
|
|
|
— |
|
Other assets |
|
|
317 |
|
|
|
(469 |
) |
|
|
(137 |
) |
Accounts payable |
|
|
5,215 |
|
|
|
(2,350 |
) |
|
|
2,813 |
|
Accrued expenses |
|
|
(12,008 |
) |
|
|
8,569 |
|
|
|
2,562 |
|
Contract liabilities |
|
|
(1,625 |
) |
|
|
518 |
|
|
|
636 |
|
Lease liabilities |
|
|
(845 |
) |
|
|
(1,004 |
) |
|
|
(653 |
) |
Net cash used in operating activities |
|
|
(68,571 |
) |
|
|
(22,049 |
) |
|
|
(27,125 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|||
Purchase of marketable securities |
|
|
(267,467 |
) |
|
|
— |
|
|
|
— |
|
Proceeds from sale of marketable securities |
|
|
235,000 |
|
|
|
— |
|
|
|
— |
|
Purchase of short-term investments |
|
|
— |
|
|
|
(17,711 |
) |
|
|
(28,850 |
) |
Proceeds from short-term investments |
|
|
— |
|
|
|
28,571 |
|
|
|
30,470 |
|
Purchases of property and equipment |
|
|
(6,262 |
) |
|
|
(4,190 |
) |
|
|
(2,693 |
) |
Proceeds from life insurance |
|
|
627 |
|
|
|
— |
|
|
|
— |
|
Proceeds from sale of property and equipment |
|
|
— |
|
|
|
— |
|
|
|
155 |
|
Cash paid for business combinations, net of cash acquired |
|
|
(174,646 |
) |
|
|
— |
|
|
|
(1,432 |
) |
Net cash (used in) provided by investing activities |
|
|
(212,748 |
) |
|
|
6,670 |
|
|
|
(2,350 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|||
Proceeds from issuance of Series A-2, Series B, Series C, Series D and Series E convertible preferred stock, net of issuance costs |
|
|
— |
|
|
|
52,409 |
|
|
|
54,929 |
|
Repurchase of Series A-2, Series B, Series C and Series D convertible preferred stock |
|
|
— |
|
|
|
(12,852 |
) |
|
|
— |
|
Deemed dividend to preferred stockholders |
|
|
— |
|
|
|
(8,801 |
) |
|
|
— |
|
Proceeds from initial public offering, net of underwriters' discount |
|
|
325,263 |
|
|
|
— |
|
|
|
— |
|
Payments in connection with initial public offering |
|
|
(3,678 |
) |
|
|
— |
|
|
|
— |
|
Proceeds from stock options exercised |
|
|
2,291 |
|
|
|
518 |
|
|
|
450 |
|
Proceeds from the exercise of warrants |
|
|
40 |
|
|
|
— |
|
|
|
— |
|
Proceeds from term loan |
|
|
— |
|
|
|
4,000 |
|
|
|
— |
|
Payment on line of credit, net |
|
|
— |
|
|
|
— |
|
|
|
(500 |
) |
Repayment of term loan |
|
|
(16,136 |
) |
|
|
— |
|
|
|
— |
|
Proceeds from other borrowings |
|
|
— |
|
|
|
4,783 |
|
|
|
— |
|
Repayment of other borrowings |
|
|
— |
|
|
|
(4,783 |
) |
|
|
— |
|
Payments on finance lease obligations |
|
|
(12 |
) |
|
|
(13 |
) |
|
|
(164 |
) |
Net cash provided by financing activities |
|
|
307,768 |
|
|
|
35,261 |
|
|
|
54,715 |
|
Effect of foreign currency translation on cash and cash equivalents |
|
|
(61 |
) |
|
|
(130 |
) |
|
|
— |
|
Net increase in cash and cash equivalents |
|
|
26,388 |
|
|
|
19,752 |
|
|
|
25,240 |
|
Cash and cash equivalents at beginning of the year |
|
|
59,874 |
|
|
|
40,122 |
|
|
|
14,882 |
|
Cash and cash equivalents at end of the year |
|
$ |
86,262 |
|
|
$ |
59,874 |
|
|
$ |
40,122 |
|
Supplemental cash flow information: |
|
|
|
|
|
|
|
|
|
|||
Cash paid for interest |
|
$ |
907 |
|
|
$ |
1,269 |
|
|
$ |
1,111 |
|
Non-cash investing activity: |
|
|
|
|
|
|
|
|
|
|||
Non-cash consideration in connection with business combination |
|
$ |
105,227 |
|
|
$ |
— |
|
|
$ |
2,743 |
|
9
Xometry, Inc. and Subsidiaries
Unaudited Reconciliations of Non-GAAP Financial Measures
(In thousands)
|
|
Three Months Ended December 31, |
|
|
For the Year Ended December 31, |
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Adjusted EBITDA: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
$ |
(23,907 |
) |
|
$ |
(10,178 |
) |
|
$ |
(61,381 |
) |
|
$ |
(31,085 |
) |
Add (deduct): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense, interest and dividend income and other expenses |
|
|
1,374 |
|
|
|
805 |
|
|
|
2,736 |
|
|
|
1,869 |
|
Depreciation and amortization(1) |
|
|
1,292 |
|
|
|
864 |
|
|
|
3,596 |
|
|
|
3,120 |
|
Charitable contribution of common stock |
|
|
1,084 |
|
|
|
— |
|
|
|
2,242 |
|
|
|
— |
|
Stock-based compensation(2) |
|
|
2,648 |
|
|
|
327 |
|
|
|
7,395 |
|
|
|
1,006 |
|
Transaction costs |
|
|
5,696 |
|
|
|
— |
|
|
|
5,696 |
|
|
|
— |
|
Income from unconsolidated joint venture |
|
|
(41 |
) |
|
|
— |
|
|
|
(41 |
) |
|
|
— |
|
Impairment of goodwill and intangible assets |
|
|
— |
|
|
|
1,592 |
|
|
|
— |
|
|
|
1,592 |
|
Adjusted EBITDA |
|
$ |
(11,854 |
) |
|
$ |
(6,590 |
) |
|
$ |
(39,757 |
) |
|
$ |
(23,498 |
) |
10
Xometry, Inc. and Subsidiaries
Segment Results
(In thousands)
|
|
Three Months Ended December 31, |
|
|
For the Year Ended December 31, |
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Segment Revenue: |
|
(unaudited) |
|
|
(unaudited) |
|
|
|
|
|||||||
U.S. |
|
$ |
61,769 |
|
|
$ |
36,734 |
|
|
$ |
202,034 |
|
|
$ |
138,272 |
|
International |
|
|
5,329 |
|
|
|
1,246 |
|
|
|
16,302 |
|
|
|
3,134 |
|
Total revenue |
|
$ |
67,098 |
|
|
$ |
37,980 |
|
|
$ |
218,336 |
|
|
$ |
141,406 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment Net Loss: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
U.S. |
|
$ |
(21,080 |
) |
|
$ |
(6,040 |
) |
|
$ |
(51,230 |
) |
|
$ |
(22,130 |
) |
International |
|
|
(2,827 |
) |
|
|
(4,138 |
) |
|
|
(10,151 |
) |
|
|
(8,955 |
) |
Total net loss |
|
$ |
(23,907 |
) |
|
$ |
(10,178 |
) |
|
$ |
(61,381 |
) |
|
$ |
(31,085 |
) |
11
Xometry, Inc. and Subsidiaries
Supplemental Information
(In thousands)
|
|
Three Months Ended December 31, |
|
|
For the Year Ended December 31, |
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Summary of Stock-based Compensation Expense |
|
(unaudited) |
|
|
(unaudited) |
|
|
|
|
|||||||
Sales and marketing |
|
$ |
533 |
|
|
$ |
51 |
|
|
$ |
1,223 |
|
|
$ |
156 |
|
Operations and support |
|
|
1,295 |
|
|
|
84 |
|
|
|
2,659 |
|
|
|
259 |
|
Product development |
|
|
765 |
|
|
|
122 |
|
|
|
1,744 |
|
|
|
375 |
|
General and administrative |
|
|
55 |
|
|
|
70 |
|
|
|
1,769 |
|
|
|
216 |
|
Total stock-based compensation expense |
|
$ |
2,648 |
|
|
$ |
327 |
|
|
$ |
7,395 |
|
|
$ |
1,006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Summary of Depreciation and Amortization Expense |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of revenue |
|
$ |
34 |
|
|
$ |
52 |
|
|
$ |
104 |
|
|
$ |
230 |
|
Sales and marketing |
|
|
211 |
|
|
|
157 |
|
|
|
300 |
|
|
|
665 |
|
Operations and support |
|
|
36 |
|
|
|
52 |
|
|
|
155 |
|
|
|
196 |
|
Product development |
|
|
909 |
|
|
|
500 |
|
|
|
2,821 |
|
|
|
1,720 |
|
General and administrative |
|
|
102 |
|
|
|
103 |
|
|
|
216 |
|
|
|
309 |
|
Total depreciation and amortization expense |
|
$ |
1,292 |
|
|
$ |
864 |
|
|
$ |
3,596 |
|
|
$ |
3,120 |
|
For the three and twelve months ended December 31, 2021, general and administrative expense includes $1.1 million and $2.2 million, respectively of expense related to charitable contributions.
12
Document And Entity Information |
Mar. 17, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Mar. 17, 2022 |
| Entity Registrant Name | Xometry, Inc. |
| Entity Central Index Key | 0001657573 |
| Entity Emerging Growth Company | true |
| Entity File Number | 001-40546 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 32-0415449 |
| Entity Address, Address Line One | 7529 Standish Place, Suite 200 |
| Entity Address, City or Town | Derwood |
| Entity Address, State or Province | MD |
| Entity Address, Postal Zip Code | 20855 |
| City Area Code | (240) |
| Local Phone Number | 335-7914 |
| Entity Information, Former Legal or Registered Name | Not applicable |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | false |
| Title of 12(b) Security | Class A common stock, par value $0.000001 per share |
| Trading Symbol | XMTR |
| Security Exchange Name | NASDAQ |